Symptomatische Therapie bei nephrotischem Syndrom

.

[1]  H. Debiec,et al.  Antigen identification in membranous nephropathy moves toward targeted monitoring and new therapy. , 2010, Journal of the American Society of Nephrology : JASN.

[2]  Robert R. Quinn,et al.  Relation between kidney function, proteinuria, and adverse outcomes. , 2010, JAMA.

[3]  G. Navis,et al.  Benefits of dietary sodium restriction in the management of chronic kidney disease , 2009, Current opinion in nephrology and hypertension.

[4]  C. Antignac,et al.  Genetics of nephrotic syndrome: connecting molecular genetics to podocyte physiology. , 2009, Human molecular genetics.

[5]  G. Remuzzi,et al.  Proteinuria: Is the ONTARGET renal substudy actually off target? , 2009, Nature Reviews Nephrology.

[6]  Lars E. Rydn,et al.  Effect of Telmisartan on Renal Outcomes , 2009, Annals of Internal Medicine.

[7]  E. Burgess,et al.  Supramaximal dose of candesartan in proteinuric renal disease. , 2009, Journal of the American Society of Nephrology : JASN.

[8]  T. Ikizler.  Dietary protein restriction in CKD: the debate continues. , 2009, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[9]  J. Dear,et al.  Setting the stage for acute-on-chronic kidney injury. , 2008, Kidney international.

[10]  G. McMahon,et al.  Intensive glycemic control in the ACCORD and ADVANCE trials. , 2008, The New England journal of medicine.

[11]  E. Lewis,et al.  Aliskiren combined with losartan in type 2 diabetes and nephropathy. , 2008, The New England journal of medicine.

[12]  G. Remuzzi,et al.  Role of remission clinics in the longitudinal treatment of CKD. , 2008, Journal of the American Society of Nephrology : JASN.

[13]  G. Navis,et al.  Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan. , 2008, Journal of the American Society of Nephrology : JASN.

[14]  J. Kastelein,et al.  Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. , 2007, Clinical journal of the American Society of Nephrology : CJASN.

[15]  J. Griffith,et al.  Lowest systolic blood pressure is associated with stroke in stages 3 to 4 chronic kidney disease. , 2007, Journal of the American Society of Nephrology : JASN.

[16]  F. Luft,et al.  Direct renin inhibition with aliskiren in hypertension and target organ damage. , 2006, Clinical journal of the American Society of Nephrology : CJASN.

[17]  N. Markandu,et al.  Modest Salt Reduction Reduces Blood Pressure and Urine Protein Excretion in Black Hypertensives: A Randomized Control Trial , 2005, Hypertension.

[18]  C. Delcroix,et al.  Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents. , 2005, Journal of the American Society of Nephrology : JASN.

[19]  S. Yusuf,et al.  Effect of Ramipril in Reducing Sudden Deaths and Nonfatal Cardiac Arrests in High-Risk Individuals Without Heart Failure or Left Ventricular Dysfunction , 2004, Circulation.

[20]  E. Portnay,et al.  Modulation of the renin-angiotensin-aldosterone system for the secondary prevention of stroke , 2004, Neurology.

[21]  G. Bakris,et al.  Differential effects of calcium antagonist subclasses on markers of nephropathy progression. , 2004, Kidney international.

[22]  Sunil V. Rao,et al.  Management of glomerular proteinuria: a commentary. , 2003, Journal of the American Society of Nephrology : JASN.

[23]  Christopher H Schmid,et al.  Progression of Chronic Kidney Disease: The Role of Blood Pressure Control, Proteinuria, and Angiotensin-Converting Enzyme Inhibition: A Patient-Level Meta-Analysis , 2003, Annals of Internal Medicine.

[24]  R. Hayward,et al.  Treatment of Hypertension in Type 2 Diabetes Mellitus: Blood Pressure Goals, Choice of Agents, and Setting Priorities in Diabetes Care , 2003, Annals of Internal Medicine.

[25]  Mark A B Thomas,et al.  Statin therapy improves brachial artery endothelial function in nephrotic syndrome. , 2002, Kidney international.

[26]  B. Brenner,et al.  Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. , 2001, The New England journal of medicine.

[27]  S. Yusuf,et al.  Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. , 2001, JAMA.

[28]  Keith C. Norris,et al.  Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. , 2001, JAMA.

[29]  G. Bakris,et al.  Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. , 2000, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[30]  Giuseppe Remuzzi,et al.  Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria , 1999, The Lancet.

[31]  L Peltonen,et al.  Positionally cloned gene for a novel glomerular protein--nephrin--is mutated in congenital nephrotic syndrome. , 1998, Molecular cell.

[32]  The Gisen Group.  Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy , 1997, The Lancet.

[33]  T. Greene,et al.  Blood Pressure Control, Proteinuria, and the Progression of Renal Disease , 1995, Annals of Internal Medicine.

[34]  R. Hené,et al.  EFFECTS OF SIMVASTATIN AND CHOLESTYRAMINE ON LIPOPROTEIN PROFILE IN HYPERLIPIDAEMIA OF NEPHROTIC SYNDROME , 1988, The Lancet.

[35]  R. Garrick.  Bicarbonate Supplementation Slows Progression of CKD and Improves Nutritional Status , 2010 .

[36]  R. Garrick.  Meta-analysis: Effect of Monotherapy and Combination Therapy with Inhibitors of the Renin–Angiotensin System on Proteinuria in Renal Disease , 2009 .

[37]  G. Bakris,et al.  Antihypertensive therapy in the presence of proteinuria. , 2007, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[38]  Matthias Kretzler,et al.  Cell biology of the glomerular podocyte. , 2003, Physiological reviews.

[39]  G. Remuzzi,et al.  ACE genotype and ACE inhibitors induced renoprotection in chronic proteinuric nephropathies1. , 2000, Kidney international.